Listing - December 29, 2020
LIDDS to apply for listing on Nasdaq Stockholm Main Market
A listing on Nasdaq Stockholm Main Market is a natural next step in the company’s development, it states. “A move to Nasdaq Stockholm’s main market can contribute to increased interest from a broader investor base while at the same time increase the visibility and exposure of LIDDS, in Sweden and globally,” says Monica Wallter, CEO, […]
Pharma Business - May 19, 2020
Positive news from LIDDS
LIDDS has received positive responses from the Swedish Medical Products Agency and Phase IIb study results indicate cancer control. The company has received positive responses from the Swedish Medical Products Agency (MPA) regarding the proposed design of the Phase III study of Liproca Depot for patients with localized prostate cancer, within the intermediate risk group. […]
New Market - January 23, 2020
LIDDS’s Nanozolid registered in the US
LIDDS has announced that the United States Patent and Trademark Office has registered the trademark NanoZolid. LIDDS thereby has exclusive rights to the trademark for products and services in the USA and in the EU, where NanoZolid has been registered since 2016. “This is an essential, although expected, step in establishing the concept of LIDDS […]
Clinical Trials - November 8, 2019
LIDDS licensee prepares for phase III trial in China
LIDDS licensee Jiangxi Puheng Pharma has after reviewing the preliminary results in LPC-004 decided to move ahead and has initiated discussions with Chinese medical authority, CFDA. The phase III study protocol will be developed in close collaboration with LIDDS. An exclusive agreement LIDDS signed in 2018 an exclusive license agreement for Liproca Depot for Mainland […]
Clinical Trials - November 6, 2019
LIDDS adds Lithuanian clinics to phase I study
LIDDS has received approval from authorities in Lithuania to conduct its Phase I study, NZ-DTX-001. The aim of the phase I dose escalation clinical trial is to assess the tolerability and safety of intratumoral injections of NanoZolid with docetaxel, a well-established cytostatic used in the treatment of cancer with an estimated global market of over […]
Clinical Trials - October 23, 2019
LIDDS’s Liproca Depot open label extension study indicates PSA reduction for up to one year
Data from a voluntary open label extension (OLE) study indicates longer PSA effect with Liproca Depot in prostate cancer patients than anticipated. In half of the patients it has taken between 8 to 10 months from the initial Liproca Depot injection until they have returned to the same PSA levels as before treatment. In some […]
